CoChat
Sign Up
Cited by 73

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Cholesterol in neurologic disorders of the elderly: stroke and Alzheimer’s disease

Reiss, Allison B, Siller, Keith A, Rahman, Mohammad M, Chan, Edwin S.L, Ghiso, Jorge, de Leon, Mony J·2004·Neurobiology of Aging
DOI 10.1016/j.neurobiolaging.2003.11.009
Open this paper in CoChat — free account

Abstract

Mechanisms for the regulation of intracellular cholesterol levels in various types of brain and vascular cells are of considerable importance in our understanding of the pathogenesis of a variety of diseases, particularly atherosclerosis and Alzheimer's disease (AD). It is increasingly clear that conversion of brain cholesterol into 24-hydroxycholesterol and its subsequent release into the periphery is important for the maintenance of brain cholesterol homeostasis. Recent studies have shown elevated plasma concentrations of 24-hydroxycholesterol in patients with AD and vascular dementia, suggesting increased brain cholesterol turnover during neurodegeneration. The oxygenases involved in the degradation and excretion of cholesterol, including the cholesterol 24-hydroxylase and the 27-hydroxylase, are enzymes of the cytochrome P-450 family. This review focuses on the newly recognized importance of cholesterol and its oxygenated metabolites in the pathogenesis of ischemic stroke and AD. The reduction in stroke and AD risk in patients treated with cholesterol-lowering statins is also discussed.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.neurobiolaging.2003.11.009

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Cultured cells lacking apoE supplementation likely underestimate physiological GM1 domain size, especially those derived from the brain where cholesterol is high.

    “Our data suggest cultured cells lacking apoE supplementation likely underestimate physiological GM1 domain size, especially those derived from the brain where cholesterol is high (76).”

    From Regulation of beta-amyloid production in neurons by astrocyte-derived cholesterol (2021) · cites this paper as [76]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 126

  1. Ames, 2002, Anticardiolipin antibody titre and plasma homocysteine level independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies, Lupus, 11, 208, 10.1191/0961203302lu165oa · DOI
  2. Anderson, 1990, Rates of cholesterol, ubiquinone, dolichol, and dolichyl-P biosynthesis in rat brain slices, FEBS Lett., 269, 15, 10.1016/0014-5793(90)81107-Y · DOI
  3. Anderson, 1995, The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent vasomotion, N. Engl. J. Med., 332, 488, 10.1056/NEJM199502233320802 · DOI
  4. Ansell, 2000, Cholesterol, stroke risk, and stroke prevention, Curr. Atheroscler. Rep., 2, 92, 10.1007/s11883-000-0101-5 · DOI
  5. Benfante, 1994, Elevated serum cholesterol is a risk factor for both coronary heart disease and thromboembolic stroke in Hawaiian Japanese men. Implications of shared risk, Stroke, 25, 814, 10.1161/01.STR.25.4.814 · DOI
  6. Björkhem, 2002, Do oxysterols control cholesterol homeostasis?, J. Clin. Invest., 110, 725, 10.1172/JCI0216388 · DOI
  7. Bloch, 1983, Sterol structure and membrane function, CRC Crit. Rev. Biochem., 14, 47, 10.3109/10409238309102790 · DOI
  8. Bonita, 1992, Epidemiology of stroke, Lancet, 339, 342, 10.1016/0140-6736(92)91658-U · DOI
  9. Bots, 1997, Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study, Circulation, 96, 1432, 10.1161/01.CIR.96.5.1432 · DOI
  10. Botti, 1991, Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects, Clin. Neuropharmacol., 14, 256, 10.1097/00002826-199106000-00010 · DOI
  11. Brown, 1993, Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease, Circulation, 87, 1781, 10.1161/01.CIR.87.6.1781 · DOI
  12. Calero, 2000, Apolipoprotein J (clusterin) and Alzheimer’s disease, Microsc. Res. Tech., 50, 305, 10.1002/1097-0029(20000815)50:4<305::AID-JEMT10>3.0.CO;2-L · DOI
  13. Cali, 1991, Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis, J. Biol. Chem., 266, 7779, 10.1016/S0021-9258(20)89518-0 · DOI
  14. Christiansen-Weber, 2000, Functional loss of ABCA1 in mice causes severe placental malformation, aberrant lipid distribution, and kidney glomerulonephritis as well as high-density lipoprotein cholesterol deficiency, Am. J. Pathol., 157, 1017, 10.1016/S0002-9440(10)64614-7 · DOI
  15. Cook RP. Cholesterol. Chemistry, biochemistry, and pathology. New York: Academic Press; 1958. p. 1–542.
  16. Corder, 1993, Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families, Science, 261, 921, 10.1126/science.8346443 · DOI · Paper page
  17. Costet, 2000, Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor, J. Biol. Chem., 275, 28240, 10.1074/jbc.M003337200 · DOI
  18. Crisby, 2002, Statins in the prevention and treatment of Alzheimer disease, Alzheimer Dis. Assoc. Disord., 16, 131, 10.1097/00002093-200207000-00001 · DOI
  19. Crouse, 1998, HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data, Atherosclerosis, 138, 11, 10.1016/S0021-9150(98)00014-8 · DOI
  20. Danik, 1999, Brain lipoprotein metabolism and its relation to neurodegenerative disease, Crit. Rev. Neurobiol., 13, 357, 10.1615/CritRevNeurobiol.v13.i4.20 · DOI
  21. de Leon, 2001, Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET), Proc. Natl. Acad. Sci. U.S.A., 98, 10966, 10.1073/pnas.191044198 · DOI · Paper page
  22. Demchuk, 1999, Is cholesterol a risk factor for stroke? Yes, Arch. Neurol., 56, 1518, 10.1001/archneur.56.12.1518 · DOI
  23. Desai, 2002, Genetic variation in the cholesterol 24-hydroxylase (CYP46) gene and the risk of Alzheimer’s disease, Neurosci. Lett., 328, 9, 10.1016/S0304-3940(02)00443-3 · DOI
  24. Di Mascio, 2000, Cholesterol reduction and stroke occurrence: an overview of randomized controlled trials, Cerebrovasc. Dis., 10, 85, 10.1159/000016035 · DOI
  25. Di Napoli, 2002, Statins and stroke: evidence for cholesterol-independent effects, Eur. Heart J., 23, 1908, 10.1053/euhj.2002.3236 · DOI
  26. Dietschy, 1983, Cholesterol synthesis in vivo and in vitro in the WHHL rabbit, an animal with defective low density lipoprotein receptors, J. Lipid Res., 24, 469, 10.1016/S0022-2275(20)37988-8 · DOI
  27. Endres, 1998, Stroke protection by 3-hydroxy-3-mehylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase, Proc. Natl. Acad. Sci. USA, 95, 8880, 10.1073/pnas.95.15.8880 · DOI
  28. Falk, 1995, Coronary plaque disruption, Circulation, 92, 657, 10.1161/01.CIR.92.3.657 · DOI · Paper page
  29. Farhangrazi, 1997, High density lipoprotein decreases beta-amyloid toxicity in cortical cell culture, Neuroreport, 8, 1127, 10.1097/00001756-199703240-00013 · DOI
  30. Fassbender, 2001, Simvastatin strongly reduces levels of Alzheimer’s disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo, Proc. Natl. Acad. Sci. USA, 98, 5856, 10.1073/pnas.081620098 · DOI · Paper page
  31. Fielding, 1995, Molecular physiology of reverse cholesterol transport, J. Lipid Res., 36, 211, 10.1016/S0022-2275(20)39898-9 · DOI · Paper page
  32. Forte, 1995, Recruitment of cell phospholipids and cholesterol by apolipoproteins A-II and A-I: formation of nascent apolipoprotein-specific HDL that differ in size, phospholipid composition, and reactivity with LCAT, J. Lipid Res., 36, 148, 10.1016/S0022-2275(20)39763-7 · DOI
  33. Fu, 2001, 27-Hydroxycholesterol is an endogenous ligand for LXR in cholesterol-loaded cells, J. Biol. Chem., 276, 38378, 10.1074/jbc.M105805200 · DOI
  34. Fujiyama, 1991, Atherogenic risk factors in cerebrotendinous xanthomatosis, Clinica Chimica Acta, 200, 1, 10.1016/0009-8981(91)90328-A · DOI
  35. Ghiso, 2001, Cerebral amyloidosis, amyloid angiopathy, and their relationship to stroke and dementia, J. Alzheimers Dis., 3, 65, 10.3233/JAD-2001-3110 · DOI
  36. Gromadzka, 1999, Presence of immune complexes in ischemic stroke, Neurol. Neurochir. Pol., 33, 301
  37. Hamon, 2000, ABC1 promotes engulfment of apoptotic cells and transbilayer redistribution of phosphatidylserine, Nat. Cell Biol., 2, 399, 10.1038/35017029 · DOI
  38. Herrmann, 2002, Cognitive pharmacotherapy of Alzheimer’s disease and other dementias, Can. J. Psychiatry, 47, 715, 10.1177/070674370204700802 · DOI
  39. Hulthe, 1997, Atherosclerotic changes in the carotid artery bulb as measured by B-mode ultrasound are associated with the extent of coronary atherosclerosis, Stroke, 28, 1189, 10.1161/01.STR.28.6.1189 · DOI
  40. Iso, 1989, Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial, N. Engl. J. Med., 320, 904, 10.1056/NEJM198904063201405 · DOI
  41. Jackson SM, Ericsson J, Edwards PA. In: Bittman R, editor. Cholesterol: its functions and metabolism in biology and medicine. New York: Plenum Press; 1997. p. 1–22. · DOI
  42. Jick, 2000, Statins and the risk of dementia, Lancet, 356, 1627, 10.1016/S0140-6736(00)03155-X · DOI
  43. Joensuu, 1994, Determinants of femoral and carotid artery atherosclerosis, J. Intern. Med., 236, 79, 10.1111/j.1365-2796.1994.tb01123.x · DOI
  44. Jurevics, 1995, Cholesterol for synthesis of myelin is made locally, not imported into brain, J. Neurochem., 64, 895, 10.1046/j.1471-4159.1995.64020895.x · DOI · Paper page
  45. Kalaria, 2002, Similarities between Alzheimer’s disease and vascular dementia, J. Neurol. Sci., 203/204, 29, 10.1016/S0022-510X(02)00256-3 · DOI
  46. Kalaria, 1999, The blood–brain barrier and cerebrovascular pathology in Alzheimer’s disease, Ann. N.Y. Acad. Sci., 893, 113, 10.1111/j.1749-6632.1999.tb07821.x · DOI
  47. Kiener, 1995, Immune complexes of LDL induce atherogenic responses in human monocytic cells, Arterioscler. Thromb. Vasc. Biol., 15, 990, 10.1161/01.ATV.15.7.990 · DOI
  48. Kneisel, 2000, Tight junctions of the blood-brain barrier, Cell Mol. Neurobiol., 20, 57, 10.1023/A:1006995910836 · DOI
  49. Knopp, 1999, Drug treatment of lipid disorders, N. Engl. J. Med., 341, 498, 10.1056/NEJM199908123410707 · DOI
  50. Koldamova RP, Lefterov IM, Ikonomovic, MD, Skoko J, Lefterov PI, Isanski BA, DeKosky ST, Lazo JS. 22R-Hydroxycholesterol and 9-cis-retinoic acid induce ABCA1 transporter expression and cholesterol efflux in brain cells and decrease Abeta secretion. J Biol Chem 2003 (epublished). · DOI · Paper page
  51. Kolsch, 2002, Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer’s disease, Mol. Psychiatry, 7, 899, 10.1038/sj.mp.4001109 · DOI
  52. Koudinov, 2001, Essential role for cholesterol in synaptic plasticity and neuronal degeneration, FASEB J., 15, 1858, 10.1096/fj.00-0815fje · DOI
  53. Krieger, 1998, The “best” of cholesterols, the “worst” of cholesterols: a tale of two receptors, Proc. Natl. Acad. Sci. U.S.A, 95, 4077, 10.1073/pnas.95.8.4077 · DOI
  54. Kuipers F, Elferink RPJO, Verkade HJ, Groen AK. In: Bittman R, editor. Cholesterol: its functions and metabolism in biology and medicine. New York: Plenum Press; 1997. p. 295–318. · DOI
  55. Langmann, 1999, Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1): evidence for sterol-dependent regulation in macrophages, Biochem. Biophys. Res. Commun, 257, 29, 10.1006/bbrc.1999.0406 · DOI
  56. Lehmann, 1997, Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway, J. Biol. Chem., 272, 3137, 10.1074/jbc.272.6.3137 · DOI · Paper page
  57. Leoni V, Masterman T, Patel P, Meaney S, Diczfalusy U, Bjorkhem I. Side-chain oxidised oxysterols in cerebrospinal fluid and integrity of blood-brain and blood-CSF barriers. J Lipid Res 2003 (e-published ahead of print). · DOI
  58. Liu, 1999, Understanding the biological activity of amyloid proteins in vitro: from inhibited cellular MTT reduction to altered cellular cholesterol homeostasis, Prog. Neuro-Psychopharmacol. Biol. Psychiat., 23, 377, 10.1016/S0278-5846(99)00003-2 · DOI
  59. Locatelli, 2002, Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain, Arch. Neurol., 59, 213, 10.1001/archneur.59.2.213 · DOI
  60. Lund, 1999, cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain, Proc. Natl. Acad. Sci. USA, 96, 7238, 10.1073/pnas.96.13.7238 · DOI · Paper page
  61. Lütjohann, 1996, Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation, Proc. Natl. Acad. Sci. USA, 93, 9799, 10.1073/pnas.93.18.9799 · DOI · Paper page
  62. Lutjohann, 2000, Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients, J. Lipid Res., 41, 195, 10.1016/S0022-2275(20)32052-6 · DOI
  63. Mathiesen, 2001, Echolucent plaques are associated with high risk of ischemic cerebrovascular events in carotid stenosis: the Tromsø Study, Circulation, 103, 2171, 10.1161/01.CIR.103.17.2171 · DOI
  64. McNeish, 2000, High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1, Proc. Natl. Acad. Sci. USA, 97, 4245, 10.1073/pnas.97.8.4245 · DOI
  65. Mercuri, 1996, Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study, Am. J. Med., 101, 627, 10.1016/S0002-9343(96)00333-6 · DOI
  66. Meyer, 2001, Atherosclerosis and connective tissue diseases, Joint Bone Spine, 68, 564, 10.1016/S1297-319X(01)00330-X · DOI
  67. Morell, 1996, Origin of cholesterol in myelin, Neurochem. Res., 21, 463, 10.1007/BF02527711 · DOI
  68. Mori, 2001, Cholesterol accumulates in senile plaques of Alzheimer disease patients and in transgenic APPsw mice, J. Neuropathol. Exp. Neurol., 60, 778, 10.1093/jnen/60.8.778 · DOI · Paper page
  69. Nunan, 2002, Proteolytic processing of the amyloid-beta protein precursor of Alzheimer’s disease, Essays Biochem., 38, 37, 10.1042/bse0380037 · DOI
  70. O’Donnell, 1985, Correlation of B-mode ultrasound image and arteriography with pathologic findings at carotid endarterectomy, Arch. Surg., 120, 443, 10.1001/archsurg.1985.01390280037009 · DOI
  71. Oftebro, 1980, Cerebrotendinous xanthomatosis, J. Clin. Invest., 65, 1418, 10.1172/JCI109806 · DOI
  72. Ohvo-Rekila, 2002, Cholesterol interactions with phospholipids in membranes, Prog. Lipid Res., 41, 66, 10.1016/S0163-7827(01)00020-0 · DOI · Paper page
  73. Olesen, 2000, High density lipoprotein inhibits assembly of amyloid beta-peptides into fibrils, Biochem. Biophys. Res. Commun., 270, 62, 10.1006/bbrc.2000.2372 · DOI
  74. Oram, 1996, Apolipoprotein-mediated removal of cellular cholesterol and phospholipids, J. Lipid Res., 37, 2473, 10.1016/S0022-2275(20)37453-8 · DOI
  75. Papadakis, 1998, Lipids and stroke: neglect of a useful preventive measure?, Cardiovasc. Res., 40, 265, 10.1016/S0008-6363(98)00222-3 · DOI
  76. Papassotiropoulos, 2000, Plasma 24S-hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer’s disease, NeuroReport, 11, 1959, 10.1097/00001756-200006260-00030 · DOI
  77. Papassotiropoulos, 2003, Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism, Arch. Neurol., 60, 29, 10.1001/archneur.60.1.29 · DOI
  78. Peet, 1998, Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR, Cell, 93, 693, 10.1016/S0092-8674(00)81432-4 · DOI
  79. Polak, 1998, Hypoechoic plaque at US of the carotid artery: an independent risk factor for incident stroke in adults aged 65 years or older, Radiology, 208, 649, 10.1148/radiology.208.3.9722841 · DOI
  80. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 1995;346:1647–53. · DOI
  81. Quion, 1994, Clinical pharmacokinetics of pravastatin, Clin. Pharmacokinet., 27, 94, 10.2165/00003088-199427020-00002 · DOI
  82. Reese, 1967, Fine structure localization of a BBB to exogenous peroxidase, J. Cell Biol., 36, 207, 10.1083/jcb.34.1.207 · DOI · Paper page
  83. Refolo, 2001, A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer’s disease, Neurobiol. Dis., 8, 890, 10.1006/nbdi.2001.0422 · DOI
  84. Refolo, 2000, Hypercholesterolemia accelerates the Alzheimer’s amyloid pathology in a transgenic mouse model, Neurobiol. Dis., 7, 321, 10.1006/nbdi.2000.0304 · DOI · Paper page
  85. Reinhart, 1987, Subcellular localization of the enzymes of cholesterol biosynthesis and metabolism in rat liver, J. Biol. Chem., 262, 9649, 10.1016/S0021-9258(18)47983-5 · DOI
  86. Reiss, 2000, Cytochrome P450 cholesterol 27-hydroxylase: an anti-atherogenic enzyme, Recent Res. Devel Lipids Res., 4, 39
  87. Reiss, 2001, Immune complexes and interferon-γ decrease cholesterol 27-hydroxylase in human arterial endothelium and macrophages, J. Lipid Res., 42, 1913, 10.1016/S0022-2275(20)31518-2 · DOI
  88. Reiss, 2001, Immune modulation of cholesterol homeostasis, Recent Res. Devel Protein Eng., 1, 21
  89. Rockwood, 2002, Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people, Arch. Neurol., 59, 223, 10.1001/archneur.59.2.223 · DOI
  90. Rothblat, 1992, Apolipoproteins, membrane cholesterol domains, and the regulation of cholesterol efflux, J. Lipid Res., 33, 1091, 10.1016/S0022-2275(20)40761-8 · DOI
  91. Rust, 1999, Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1, Nat. Genet., 22, 352, 10.1038/11921 · DOI · Paper page
  92. Sacco, 2001, High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study, JAMA, 285, 2729, 10.1001/jama.285.21.2729 · DOI · Paper page
  93. Schwartz, 2000, ABC1 gene expression and ApoA-I-mediated cholesterol efflux are regulated by LXR, Biochem. Biophys. Res. Commun., 274, 794, 10.1006/bbrc.2000.3243 · DOI
  94. Segrest, 1992, The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function, J. Lipid Res., 33, 141, 10.1016/S0022-2275(20)41536-6 · DOI
  95. Selkoe, 1994, Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer’s disease, Annu. Rev. Cell Biol., 10, 373, 10.1146/annurev.cb.10.110194.002105 · DOI
  96. Shiomi, 1995, Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques: effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits, Arterioscler. Thromb. Vasc. Biol., 15, 1938, 10.1161/01.ATV.15.11.1938 · DOI
  97. Simons, 2000, How cells handle cholesterol, Science, 290, 1721, 10.1126/science.290.5497.1721 · DOI
  98. Simons, 1998, Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons, Proc. Natl. Acad. Sci. USA, 95, 6460, 10.1073/pnas.95.11.6460 · DOI
  99. Simons, 2002, Treatment with simvastatin in normocholesterolemic patients with Alzheimer’s disease: a 26-week randomized, placebo-controlled, double-blind trial, Ann. Neurol., 52, 346, 10.1002/ana.10292 · DOI
  100. Skoog, 1998, A population study on blood-brain barrier function in 85-year-olds: relation to Alzheimer’s disease and vascular dementia, Neurology, 50, 966, 10.1212/WNL.50.4.966 · DOI
  101. Snowdon, 1997, Brain infarction and the clinical expression of Alzheimer disease. The Nun Study, JAMA, 277, 813, 10.1001/jama.277.10.813 · DOI · Paper page
  102. Spady, 1983, Sterol synthesis in vivo in 18 tissues of the squirrel monkey, guinea pig, rabbit, hamster and rat, J. Lipid Res., 24, 303, 10.1016/S0022-2275(20)37999-2 · DOI
  103. Sparks, 1994, Induction of Alzheimer-like beta-amyloid immunoreactive in the brains of rabbits with dietary cholesterol, Exp. Neurol., 126, 88, 10.1006/exnr.1994.1044 · DOI · Paper page
  104. Sparks, 1996, Intraneuronal beta-amyloid immunoreactivity in the CNS, Neurobiol. Aging, 17, 291, 10.1016/0197-4580(95)02067-5 · DOI
  105. Stensland-Bugge, 2001, Age and sex differences in the relationship between inherited and lifestyle risk factors and subclinical carotid atherosclerosis: the Tromso study, Atherosclerosis, 154, 437, 10.1016/S0021-9150(00)00486-X · DOI
  106. Stephens DJ, Walters CE, Davies H, Austen BM, The role of cholesterol in the biosynthesis of beta-amyloid. In: Frears ER, editor. Neuroreport, vol. 10. 1999. p. 1699–705. · DOI
  107. Subasinghe, 2003, Cholesterol is necessary both for the toxic effect of Abeta peptides on vascular smooth muscle cells and for Abeta binding to vascular smooth muscle cell membranes, J. Neurochem., 84, 471, 10.1046/j.1471-4159.2003.01552.x · DOI
  108. Tell, 1988, Relation between blood lipids, lipoproteins, and cerebrovascular atherosclerosis: a review, Stroke, 19, 423, 10.1161/01.STR.19.4.423 · DOI
  109. Tsuji, 1993, Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier, J. Pharmacol. Exp. Ther, 267, 1085
  110. Vaughan, 2001, Statin therapy and stroke prevention, Curr. Opin. Cardiol., 16, 219, 10.1097/00001573-200107000-00001 · DOI
  111. Vaughan, 2000, The evolving role of statins in the management of atherosclerosis, J. Am. Coll Cardiol., 35, 1, 10.1016/S0735-1097(99)00525-2 · DOI
  112. Vaughan, 1996, Statins do more than just lower cholesterol, Lancet, 348, 1079, 10.1016/S0140-6736(96)05190-2 · DOI
  113. Vaya, 2001, Selective distribution of oxysterols in atherosclerotic lesions and human plasma lipoproteins, Free Radic. Res., 34, 485, 10.1080/10715760100300431 · DOI
  114. Walter, 1994, The high density lipoprotein- and apolipoprotein A-I-induced mobilization of cellular cholesterol is impaired in fibroblasts from Tangier disease subjects, Biochem. Biophys. Res. Commun., 205, 850, 10.1006/bbrc.1994.2742 · DOI
  115. Wick, 1995, Is atherosclerosis an immunologically mediated disease?, Immunol. Today, 16, 27, 10.1016/0167-5699(95)80067-0 · DOI
  116. Wikstrand, 1992, Frontiers in cardiovascular science: quantitative measurements of atherosclerosis manifestations in humans, Arterioscler. Thromb., 12, 114, 10.1161/01.ATV.12.1.114 · DOI
  117. Willy, 1997, Unique requirements for retinoid-dependent transcriptional activation by the orphan receptor LXR, Genes Dev., 11, 289, 10.1101/gad.11.3.289 · DOI
  118. Wilson, 1970, The measurement of the exchangeable pools of cholesterol in the baboon, J. Clin. Invest., 49, 655, 10.1172/JCI106277 · DOI
  119. Wollmer, 2003, Papassotiropoulos A. ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer’s disease, Neurobiol. Aging, 24, 421, 10.1016/S0197-4580(02)00094-5 · DOI
  120. Wolozin, 2000, Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors, Arch. Neurol., 57, 1439, 10.1001/archneur.57.10.1439 · DOI
  121. Xavier, 2003, Clinical potential of intra-arterial thrombolytic therapy in patients with acute ischaemic stroke, CNS Drugs, 17, 213, 10.2165/00023210-200317040-00001 · DOI
  122. Yankner, 1989, Neurotoxicity of fragment of the amyloid precursor associated with Alzheimer’s disease, Science, 245, 417, 10.1126/science.2474201 · DOI · Paper page
  123. Yankner, 1996, Mechanisms of neuronal degeneration in Alzheimer’s disease, Neuron, 16, 921, 10.1016/S0896-6273(00)80115-4 · DOI
  124. Yokoyama, 1998, Apolipoprotein-mediated cellular cholesterol efflux, Biochim. Biophys. Acta, 1392, 1, 10.1016/S0005-2760(98)00032-0 · DOI
  125. Younkin, 1995, Evidence that A-beta 42 is the real culprit in Alzheimer’s disease, Annu. Neurol., 37, 287, 10.1002/ana.410370303 · DOI
  126. Zheng, 2003, Stroke: molecular mechanisms and potential targets for treatment, Curr. Mol. Med., 3, 361, 10.2174/1566524033479717 · DOI

Cited by

Sorted by citations

Metadata

Authors
Reiss, A. B., Siller, K. A., Rahman, M. M., Chan, E. S. L., Ghiso, J., & de Leon, M. J.
Venue
Neurobiology of Aging
Publisher
Elsevier BV
Published
2004-09
Volume
25
Issue
8
Pages
977-989
ISSN
0197-4580
DOI
10.1016/j.neurobiolaging.2003.11.009
Cited by
73
References
3
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review